CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,634 enrolled
Drug / intervention
Allevyn® brand silicone adhesive multilayer foam dressings +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03442777
NCT03442777N/ACompleted

Silicone Adhesive Multilayer Foam Dressings as Adjuvant Prophylactic Therapy for Pressure Ulcer (PU) Prevention: a Multicentric Randomised Open Label Parallel Group Medical Device Trial in Hospitalised Patients at Risk of PU Development

Belgium Health Care Knowledge Centre·interventional·Posted Feb 22, 2018·Updated Apr 26, 2021

In Brief

A clinical study evaluating Allevyn® brand silicone adhesive multilayer foam dressings and Mepilex® brand silicone adhesive multilayer foam dressings for Pressure Ulcer. Completed, enrolled 1,634 participants across 8 sites.

Detailed Summary

The objective of this study is to determine if silicone adhesive multilayer foam dressings applied to the sacrum, heels and greater trochanter in addition to standard prevention reduce pressure ulcer incidence category II, III, IV, Unstageable and Deep Tissue Injury (DTI) compared to standard pressure ulcer prevention alone, in at risk hospitalised patients. In particular, this trial extends previous trial results obtained in ICU setting. Therefore, only a maximum of 25% of patients will be recruited from ICU settings. The hypothesis is: 'The use of silicone adhesive multilayer foam dressings as adjuvant prophylactic therapy for pressure ulcer prevention is more effective in reducing pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) incidence rate on sacrum, heels and greater trochanter, compared to standard pressure ulcer prevention alone.' The null hypothesis is: 'The use of silicone adhesive multilayer foam dressings as adjuvant prophylactic therapy for pressure ulcer prevention is not more effective in reducing pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) incidence rate on sacrum, heels and greater trochanter, compared to standard pressure ulcer prevention alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPressure Ulcer
CountriesBelgium
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedFeb 22, 2018
Enrollment StartFeb 8, 2018
Primary CompletionDec 31, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.4 years ago

Interventions

Allevyn® brand silicone adhesive multilayer foam dressingsdevice

Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith\&Nephew (Allevyn® brand).

Mepilex® brand silicone adhesive multilayer foam dressingsdevice

Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand).